<DOC>
	<DOCNO>NCT02293837</DOCNO>
	<brief_summary>Type 1 diabetes mellitus ( T1DM ) autoimmune disease . Based previous research , study doctor think give medicine affect immune system soon diabetes diagnose may stop , delay decrease destruction beta cell , result good glucose control . Researchers believe tocilizumab could effect cell immune system think involve development type 1 diabetes . This study test whether tocilizumab help preserve delay destruction remain beta cell people recently diagnose type 1 diabetes .</brief_summary>
	<brief_title>Tocilizumab ( TCZ ) New-onset Type 1 Diabetes</brief_title>
	<detailed_description>Staggered enrollment plan trial . Prior initiate study pediatric age group ( 6-17 year old ) , 30-99 eligible adult ( age 18-45 year ) randomize 2:1 tocilizumab placebo , respectively . Once first thirty adult participant complete 12 week treatment , FDA Data Safety Monitoring Board ( DSMB ) review available data ( e.g. , interim analysis ) weigh potential risk benefit open trial pediatric participant . Current status : enrollment restrict eligible adult ( age 18 - 45 year ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Male female age 645 years* *Age eligibility criterion include subject : 6 17 year age time study enrollment 18 45 year age time study enrollment 2 . Diagnosis type 1 diabetes mellitus ( T1DM ) , use American Diabetes Association T1DM criterion , within 100 day study enrollment 3 . Positive least one diabetesrelated autoantibody , include limited : 1 . Glutamate decarboxylase ( GAD65 ) 2 . Insulin , obtain within 10 day onset exogenous insulin therapy 3 . Insulinoma antigen2 ( IA2 ) 4 . Zinc transporter8 ( ZnT8 ) 4 . Peak stimulate Cpeptide level &gt; = 0.2 pmol/mL follow mixedmeal tolerance test ( MMTT ) conduct least 21 day diagnosis within 37 day randomization ( V0 ) 5 . Signed informed consent ( informed assent minor , applicable ) . 1 . Severe reaction anaphylaxis human , humanize murine monoclonal antibody 2 . History malignancy serious uncontrolled cardiovascular , nervous system , pulmonary , renal , gastrointestinal disease , significant dyslipidemia 3 . Any history recent serious bacterial , viral , fungal , opportunistic infection 4 . Have serologic evidence current past HIV ( Human immunodeficiency virus ) , Hepatitis B , Hepatitis C 5 . Positive QuantiFERON Tuberculosis ( TB ) test , history TB , active TB infection 6 . Active infection EpsteinBarr virus ( EBV ) define EBV viral load &gt; =10,000 copy per mL whole blood 7 . Active infection Cytomegalovirus ( CMV ) define CMV viral load &gt; = 10,000 copy per mL whole blood 8 . Diagnosis liver disease elevate hepatic enzyme , define Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , &gt; 1.5 x upper limit agedetermined normal ( ULN ) total bilirubin &gt; ULN 9 . Current prior treatment know cause significant , ongoing change course T1D immunologic status 10 . Current prior ( within last 30 day ) use drug insulin treat hyperglycemia ( e.g . metformin , sulfonylurea , glinides , thiazolidinediones , exenatide , liraglutide , Dipeptidyl peptidase4 Intravenous ( DPPIV ) inhibitor , amylin ) 11 . Current use medication know significantly influence glucose tolerance ( e.g. , atypical antipsychotic , diphenylhydantoin , niacin ) 12 . Any following hematologic abnormality , confirm repeat test : 1 . White blood count &lt; 3,000/microL &gt; 14,000/microL 2 . Lymphocyte count &lt; 500/microL 3 . Platelet count &lt; 150,000 /microL Hemoglobin &lt; .5 g/dL 4 . Neutrophil count &lt; 2,000 cells/microL . 13 . Females pregnant , lactating , plan pregnancy 2 year study period 14 . History diagnose autoimmune disease exception stable thyroid celiac disease 15 . History alcohol , drug chemical abuse within 1 year prior study eligibility screen evaluation 16 . Any medical psychological condition opinion principal investigator would interfere safe completion trial 17 . Prior participation clinical trial could increase risk associated clinical trial 18 . Receipt live vaccine ( e.g . varicella , measles , mumps , rubella , coldattenuated intranasal influenza vaccine , bacillus CalmetteGu√©rin , small pox ) 6 week randomization 19 . High lipid level ( fast Lowdensity lipoprotein ( LDL ) cholesterol &gt; =160 mg/dL ) 20 . History significant allergy ( e.g . anaphylaxis ) milk soy protein .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>interleukin-6 ( IL-6 ) receptor inhibitor</keyword>
</DOC>